Skip to main content

Table 4 Presence and relative magnitude of antibodies to P. falciparum and P. vivax antigens by age in a subset of 264 participants

From: Household and individual level risk factors associated with declining malaria incidence in Meghalaya, India: implications for malaria elimination in low-endemic settings

Antigen/
Antibody
Number of seropositive individuals
n (% of age category)
Relative magnitude of response*
Relative MFI value (IQR)
Age (1–7 years)
(N = 77)
Age (8–17 years)
(N = 72)
Age (≥ 18 years)
(N = 115)
P-value^ Age (1–7 years) Age (8–17 years) Age (≥ 18 years) P-value
PfAMA1 30 (39.0%) 31 (43.1%) 98 (85.2%) < 0.001 1.21 (1.10–1.57) 1.52 (1.24–1.69) 4.83 (1.92–13.64) < 0.001
PfEBA140 13 (16.9%) 13 (18.1%) 63 (54.8%) < 0.001 2.40 (1.53–3.38) 1.86 (1.50–2.89) 2.22 (1.52–4.60) 0.720
PfEBA175 9 (11.7%) 12 (16.7%) 82 (71.3%) < 0.001 1.09 (7.35–1.79) 1.86 (1.19–2.43) 3.74 (2.15–7.45) < 0.001
PfEBA181 6 (7.8%) 15 (20.8%) 69 (60.0%) < 0.001 1.46 (1.25–2.75) 1.35 (1.19–2.90) 3.65 (1.97–6.10) 0.001
PfEtramp5.Ag1 12 (15.6%) 16 (22.2%) 67 (58.3%) < 0.001 1.34 (1.20–1.94) 1.49 (1.12–1.69) 2.25 (1.48–4.20) 0.001
PfGlurp.R2 5 (6.5%) 11 (15.3%) 60 (69.6%) < 0.001 1.77 (1.42–2.17) 1.38 (1.08–3.37) 4.72 (1.94–10.78) 0.007
PfHSP40.Ag1 9 (11.7%) 9 (12.5%) 57 (49.6%) < 0.001 1.43 (1.15–2.14) 2.05 (1.11–2.15) 1.95 (1.43–2.99) 0.077
PfMSP119 4 (5.2%) 6 (8.3%) 91 (79.1%) < 0.001 1.50 (1.12–2.29) 1.13 (1.04–1.25) 5.45 (2.70–16.35) < 0.001
PfMSP2_Ch150 3 (3.9%) 4 (5.6%) 45 (39.1%) < 0.001 1.01, 1.02, 1.39 1.11 (1.09–1.88) 1.49 (1.22–2.93) 0.058
PfMSP2_Dd2 23 (29.9%) 10 (13.9%) 68 (59.1%) 0.002 2.70 (1.36–16.19) 1.91 (1.20–2.48) 3.47 (1.92–7.71) 0.020
PfRh4.2 22 (28.6%) 20 (27.8%) 74 (64.4%) 0.001 2.62 (1.47–4.66) 2.34 (1.72–3.16) 2.21 (1.44–4.02) 0.678
PfRh2 2030 20 (26.0%) 16 (22.2%) 87 (75.7%) < 0.001 1.35 (1.14–1.86) 1.62 (1.25–2.35) 4.74 (1.99–9.80)  < 0.001
PfRh5 7 (9.1%) 14 (19.4%) 59 (51.3%) < 0.001 1.15 (1.06–2.72) 1.63 (1.14–2.11) 2.29 (1.40–3.08) 0.011
PvAMA1 2 (2.6%) 3 (4.2%) 73 (63.5%) < 0.001 1.19, 1.89 2.90 (1.25–3.28) 5.04 (2.32–14.26) 0.020
PvMSP10 28 (38.4%) 24 (33.3%) 94 (81.7%) < 0.001 1.57 (1.29–2.11) 1.43 (1.19–2.93) 2.47 (1.45–4.06) 0.002
PvMSP119 2 (2.6%) 4 (5.6%) 58 (50.4%) < 0.001 1.36, 2.14 1.61 (1.43–1.93) 2.18 (1.50–5.10) 0.218
PvMSP8 22 (28.6%) 28 (38.9%) 92 (80.0%) < 0.001 1.83 (1.16–2.60) 1.75 (1.39–3.03) 2.02 (1.40–3.31) 0.164
  1. *Only seropositive individuals were included in the analysis of each antigen
  2. ^Chi-square test for trend for difference in the proportion of seropositive individuals across age categories ( 1–7 years; 8–17 years; ≥ 18 years)
  3. Non-parametric test for trend for the difference in the magnitude of response in seropositive individuals across age categories (1–7 years; 8–17 years; ≥ 18 years)